Key result
Higher creatinine-to-cystatin C ratio linked to ~28% lower cardiometabolic multimorbidity risk per SD.
Why the study?
Does a higher normalized creatinine-to-cystatin C ratio reduce the risk of cardiometabolic multimorbidity in middle-aged and older adults?
Cohort (n=5,849)
Does a higher normalized creatinine-to-cystatin C ratio reduce the risk of cardiometabolic multimorbidity in middle-aged and older adults?
A higher normalized creatinine-to-cystatin C ratio is independently associated with a reduced risk of cardiometabolic multimorbidity in middle-aged and older Chinese adults, particularly in females.
BACKGRUOUND: Normalized creatinine-to-cystatin C ratio (NCCR) was reported to approximate relative skeletal muscle mass and diabetes risk. However, the association between NCCR and cardiometabolic multimorbidity (CMM) remains elusive. This study aimed to explore their relationship in a large-scale prospective cohort. METHODS: This study included 5,849 middle-age and older participants from the China Health and Retirement Longitudinal Study (CHARLS) enrolled between 2011 and 2012. The baseline NCCR was determined as creatinine (mg/dL)/cystatin C (mg/L)×10/body mass (kg). CMM was defined as the simultaneous occurrence of two or more of the following conditions: heart disease, stroke, and type 2 diabetes mellitus. Logistic regression analysis and Cox regression analysis were employed to estimate the relationship between NCCR and CMM. The joint effect of body mass index and NCCR on the risk of CMM were further analyzed. RESULTS: During a median 4-year follow-up, 227 (3.9%) participants developed CMM. The risk of CMM was significantly decreased with per standard deviation increase of NCCR (odds ratio, 0.72; 95% confidence interval, 0.62 to 0.85) after adjustment for confounders (P<0.001). Further sex-specific analysis found significant negative associations between NCCR and CMM in female either without or with one CMM component at baseline, which was attenuated in males but remained statistically significant among those with one basal CMM component. Notably, non-obese individuals with high NCCR levels had the lowest CMM risk compared to obese counterparts with low NCCR levels in both genders. CONCLUSION: High NCCR was independently associated with reduced risk of CMM in middle-aged and older adults in China, particularly females.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) conducted a cohort in Cardiometabolic multimorbidity (n=5,849). Normalized creatinine-to-cystatin C ratio (NCCR) vs. Lower NCCR was evaluated on Cardiometabolic multimorbidity (CMM) (OR 0.72, 95% CI 0.62-0.85, p=<0.001). A higher normalized creatinine-to-cystatin C ratio was associated with a decreased risk of cardiometabolic multimorbidity per standard deviation increase (OR 0.72; 95% CI 0.62-0.85; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: